{"id":"W4379981428","doi":"10.1002/hon.3163_t05","title":"SUNMO: PHASE III TRIAL OF MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN VERSUS RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN IN RELAPSED/REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Astellas Pharma; Pfizer","keywords":"Medicine; Rituximab; Brentuximab vedotin; Internal medicine; Oncology; Refractory (planetary science); Lymphoma; Chimeric antigen receptor; Phases of clinical research; Clinical trial; Immunotherapy; Cancer; CD30","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001018116,0.0004497789,0.002470469,0.0006755399,0.0001141023,0.00001796124,0.0003199725,0.0009974132,0.001594596],"category_scores_gemma":[0.002208521,0.0003737594,0.0002632833,0.001181749,0.0008398453,0.00008218784,0.0004101849,0.0008415933,0.0001468364],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001295034,"about_ca_system_score_gemma":0.001358821,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002784111,"about_ca_topic_score_gemma":0.0001887669,"domain_scores_codex":[0.9955235,0.0005579873,0.001312226,0.000872582,0.0007127235,0.00102103],"domain_scores_gemma":[0.9950787,0.003102877,0.0005936832,0.0006221767,0.0001824871,0.0004200483],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8631045,0.006673677,0.0005405866,0.0004372413,0.0004254853,0.01422934,0.002534003,0.00004966745,0.03143402,0.001651335,0.003501939,0.07541822],"study_design_scores_gemma":[0.9417326,0.028434,0.001977173,0.0002569823,0.000175409,0.0009317852,0.001475941,0.008136476,0.003459164,0.0005323351,0.01236687,0.0005212087],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890925,0.0009695349,0.00001982239,0.001104737,0.0007554463,0.002055214,0.00002640742,0.0001651206,0.005811258],"genre_scores_gemma":[0.9967197,0.0007231841,0.000384489,0.000150754,0.0002504976,0.0002664922,0.0001221494,0.00005969834,0.001323057],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07862817,"threshold_uncertainty_score":0.9998714,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0644506952634808,"score_gpt":0.3914333370511365,"score_spread":0.3269826417876557,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}